| A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication S Hattori, N Higashi-Kuwata, H Hayashi, SR Allu, J Raghavaiah, H Bulut, ... Nature communications 12 (1), 668, 2021 | 180 | 2021 |
| Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals K Maeda, M Amano, Y Uemura, K Tsuchiya, T Matsushima, K Noda, ... Scientific Reports 11 (1), 22848, 2021 | 78 | 2021 |
| GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection S Hattori, N Higshi-Kuwata, J Raghavaiah, D Das, H Bulut, DA Davis, ... MBio 11 (4), 10.1128/mbio. 01833-20, 2020 | 62 | 2020 |
| 4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus Y Takamatsu, Y Tanaka, S Kohgo, S Murakami, K Singh, D Das, ... Hepatology 62 (4), 1024-1036, 2015 | 56 | 2015 |
| Mechanism of darunavir (DRV)’s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop … M Aoki, D Das, H Hayashi, H Aoki-Ogata, Y Takamatsu, AK Ghosh, ... MBio 9 (2), 10.1128/mbio. 02425-17, 2018 | 55 | 2018 |
| A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency M Aoki, H Hayashi, KV Rao, D Das, N Higashi-Kuwata, H Bulut, ... Elife 6, e28020, 2017 | 55 | 2017 |
| Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma K Maeda, N Higashi-Kuwata, N Kinoshita, S Kutsuna, K Tsuchiya, ... Scientific Reports 11 (1), 5563, 2021 | 42 | 2021 |
| Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide DA Davis, S Mishra, HA Anagho, AI Aisabor, P Shrestha, V Wang, ... Oncotarget 8 (31), 50342, 2017 | 38 | 2017 |
| Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2 N Higashi-Kuwata, K Tsuji, H Hayashi, H Bulut, M Kiso, M Imai, ... Nature Communications 14 (1), 1076, 2023 | 33 | 2023 |
| Potent HIV‐1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein‐Ligand X‐ray Structural Studies AK Ghosh, Z Xia, S Kovela, WL Robinson, ME Johnson, DW Kneller, ... ChemMedChem 14 (21), 1863-1872, 2019 | 30 | 2019 |
| The high genetic barrier of EFdA/MK-8591 stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase Y Takamatsu, D Das, S Kohgo, H Hayashi, NS Delino, SG Sarafianos, ... Cell chemical biology 25 (10), 1268-1278. e3, 2018 | 25 | 2018 |
| SARS-CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response Y Takamatsu, K Omata, Y Shimizu, N Kinoshita-Iwamoto, M Terada, ... Microbiology Spectrum 10 (6), e02716-22, 2022 | 24 | 2022 |
| Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters Y Takamatsu, M Imai, K Maeda, N Nakajima, N Higashi-Kuwata, ... Journal of Virology 96 (4), e01551-21, 2022 | 24 | 2022 |
| C-5-modified tetrahydropyrano-tetrahydofuran-derived protease inhibitors (PIs) exert potent inhibition of the replication of HIV-1 variants highly resistant to various PIs … M Aoki, H Hayashi, RS Yedidi, CD Martyr, Y Takamatsu, H Aoki-Ogata, ... Journal of virology 90 (5), 2180-2194, 2016 | 17 | 2016 |
| Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral … Y Takamatsu, M Aoki, H Bulut, D Das, M Amano, VR Sheri, LC Kovari, ... Antimicrobial agents and chemotherapy 63 (8), 10.1128/aac. 00372-19, 2019 | 15 | 2019 |
| Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants K Tsuchiya, K Maeda, K Matsuda, Y Takamatsu, N Kinoshita, S Kutsuna, ... Scientific Reports 13 (1), 1263, 2023 | 14 | 2023 |
| GRL-079, a novel HIV-1 protease inhibitor, is extremely potent against multidrug-resistant HIV-1 variants and has a high genetic barrier against the emergence of resistant variants NS Delino, M Aoki, H Hayashi, S Hattori, SB Chang, Y Takamatsu, ... Antimicrobial Agents and Chemotherapy 62 (5), 10.1128/aac. 02060-17, 2018 | 11 | 2018 |
| Synthesis of 4′‐Substituted Purine 2′‐Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus S Kohgo, S Imoto, R Tokuda, Y Takamatsu, N Higashi‐Kuwata, M Aoki, ... ChemistrySelect 3 (11), 3313-3317, 2018 | 11 | 2018 |
| A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance M Aoki, SB Chang, D Das, C Martyr, NS Delino, Y Takamatsu, AK Ghosh, ... Global Health & Medicine 1 (1), 36-48, 2019 | 7 | 2019 |
| Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors AK Ghosh, M Yadav, S Iddum, S Ghazi, EK Lendy, U Jayashankar, ... European Journal of Medicinal Chemistry 267, 116132, 2024 | 6 | 2024 |
